StreetInsider.com News Articles

Adia Med adds three products to its Adia Labs lineup

Tue, 29 Sep 2026 08:02:56 -0400

Adia Med Inc. (OTCQB: ADIA), a regenerative medicine company based in Winter Park, Florida, announced that its laboratory subsidiary, Adia Labs LLC, has added three research-use products to its portfolio: Adia30M, AdiaClear, and AdiaEXO.

According to a press release, Adia30M is a stem cell product formulated at 30 million stem cells per total nucleated cells, intended for physicians who require a smaller cell quantity than the company's existing offerings. AdiaClear is an exosome-based eye drop and ear product designed for ophthalmic and otic research use. AdiaEXO is a one trillion exosome product aimed at physicians seeking lower concentrations, and is positioned

Adia Med Inc. Announces Adia Labs Expansion of Regenerative Product Line

Tue, 29 Sep 2026 08:00:00 -0400

New research-use products - Adia30M, AdiaClear, and AdiaEXO - give physicians more options in cell count, format, and concentration for investigational studies.

Winter Park, Florida--(Newsfile Corp. - September 29, 2026) - Adia Med Inc. (OTCQB: ADIA), a regenerative medicine company focused on stem cell therapies, biologics, and physician-supervised investigational research, today announced that its laboratory subsidiary, Adia Labs LLC, has expanded its product portfolio with three new research-use offerings: Adia30M, AdiaClear, and AdiaEXO.

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10520/316434_81203778979__4d3119f3-d2a2-4efc-b0a6-31b72db05a19.jpeg

The expansion is

Adia Med Inc. Announces Adia Labs Expansion of Regenerative Product Line

Tue, 29 Sep 2026 08:00:00 -0400

New research-use products - Adia30M, AdiaClear, and AdiaEXO - give physicians more options in cell count, format, and concentration for investigational studies.

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10520/316434_81203778979__4d3119f3-d2a2-4efc-b0a6-31b72db05a19.jpeg

The expansion is

Adia Med says biologic inventory tops $1.5M at Adia Labs

Tue, 22 Sep 2026 08:03:41 -0400

Adia Med Inc. (OTCQB: ADIA) announced that the estimated retail value of biologic inventory at its laboratory division, Adia Labs LLC, now exceeds $1.5 million, up from approximately $380,000 at the end of the second quarter of 2026.

According to a company press release, the inventory growth is attributed to increased product demand tied to ongoing clinical studies, higher commercial sales, and expanded supply to partner providers. The company noted that biologic inventory was reported at a carrying cost of $140,500 as of June 30, 2026, under U.S. GAAP — a figure distinct from the retail value estimate cited in the

Adia Med Inc. Announces Adia Labs Biologic Inventory Now Exceeds $1.5 Million to Meet Rising Demand for the Company's Biological Products

Tue, 22 Sep 2026 08:00:00 -0400

Winter Park, Florida--(Newsfile Corp. - September 22, 2026) - Adia Med Inc. (OTCQB: ADIA), a regenerative medicine company focused on stem cell therapies, biologics, and physician-supervised investigational research, today announced that the estimated retail value of biologic inventory at its laboratory division, Adia Labs LLC, now exceeds $1.5 million, driven by accelerating demand for the Company's biologic products as its ongoing clinical studies expand.

Management estimates that Adia Labs' biologic inventory had a retail value of approximately $380,000 at the end of the second quarter of 2026. The increase in inventory is a direct result of rising product demand tied to

Adia Med Inc. Announces Adia Labs Biologic Inventory Now Exceeds $1.5 Million to Meet Rising Demand for the Company's Biological Products

Tue, 22 Sep 2026 08:00:00 -0400

Adia Med files fifth 2026 IRB study for osteoarthritis treatment

Tue, 15 Sep 2026 08:04:39 -0400

Adia Med Inc. (OTCQB: ADIA) has submitted a clinical study protocol to an Institutional Review Board for a proposed osteoarthritis treatment using its AdiaVita product, according to a company statement.

The proposed study would evaluate a one-time intravenous infusion of AdiaVita, an umbilical cord blood-derived stem cell and exosome product, in adults with osteoarthritis. The study is structured as a patient-pay model at $5,000 per participant.

The submission is the company's fifth clinical study protocol filed in 2026. Adia Med said it plans to submit three to four additional protocols for Institutional Review Board review before year-end. Other studies in the company's

Adia Med Submits Fifth 2026 Clinical Study to IRB: Osteoarthritis Protocol for One-Time Systemic Treatment

Tue, 15 Sep 2026 08:00:00 -0400

Winter Park, Florida--(Newsfile Corp. - September 15, 2026) - Adia Med Inc. (OTCQB: ADIA), a regenerative medicine company, today announced that its subsidiary, Adia Med of Winter Park, LLC, has submitted a clinical study protocol to an Institutional Review Board for review and approval.

The proposed study is designed to evaluate a one-time systemic treatment with AdiaVita, the Company's umbilical cord blood-derived stem cell and exosome product, in adults with osteoarthritis. Participation is planned under a patient-pay model at $5,000 per patient.

This submission marks Adia Med's fifth clinical study protocol submitted in 2026. The Company also plans to submit three to

Adia Med Submits Fifth 2026 Clinical Study to IRB: Osteoarthritis Protocol for One-Time Systemic Treatment

Tue, 15 Sep 2026 08:00:00 -0400

This submission marks Adia Med's fifth clinical study protocol submitted in 2026. The Company also plans to submit three to

Nasdaq Shareholder Requirements Just Verified By Adia Med

Tue, 08 Sep 2026 08:00:00 -0400

Winter Park, Florida--(Newsfile Corp. - September 8, 2026) - Nasdaq requires companies seeking an initial listing on the Nasdaq Capital Market to have a sufficiently broad public shareholder base. That distribution test includes:

At least 300 round-lot holders;
A round-lot holder generally meaning a shareholder holding at least 100 unrestricted shares; and

Adia Med has just verified that it currently has 361 round-lot holders, or 61 holders above Nasdaq's 300-holder minimum.

Nasdaq Shareholder Requirements Just Verified By Adia Med

To view an enhanced

Nasdaq Shareholder Requirements Just Verified By Adia Med

Tue, 08 Sep 2026 08:00:00 -0400

At least 300 round-lot holders;
A round-lot holder generally meaning a shareholder holding at least 100 unrestricted shares; and

Adia Med has just verified that it currently has 361 round-lot holders, or 61 holders above Nasdaq's 300-holder minimum.

Nasdaq Shareholder Requirements Just Verified By Adia Med

To view an enhanced

From Full Sail to Full-Scale: Adia Med Inc. Assembles Intern Social Media Team

Mon, 31 Aug 2026 08:00:00 -0400

Company converts campus session at Full Sail University into an intern-led content team across YouTube, Meta, TikTok, X, and LinkedIn

Winter Park, Florida--(Newsfile Corp. - August 31, 2026) - Adia Med Inc. (OTCQB: ADIA), a regenerative medicine company focused on stem cell therapies, biologics, and advanced clinical services, today announced that its introductory innovation session earlier this month at Full Sail University delivered exactly the spark the Company was looking for — and that Adia Med has already assembled a social media team of interns to convert that momentum into a new era of organic marketing.

From Full Sail to Full-Scale: Adia Med Inc. Assembles Intern Social Media Team

Mon, 31 Aug 2026 08:00:00 -0400

Company converts campus session at Full Sail University into an intern-led content team across YouTube, Meta, TikTok, X, and LinkedIn

Adia Med hires law firm for planned Nasdaq uplisting

Mon, 24 Aug 2026 08:05:12 -0400

Adia Med Inc. (OTCQB: ADIA), a regenerative medicine company based in Winter Park, Florida, has engaged Lucosky Brookman LLP as legal counsel to assist with its planned uplisting from the OTC Markets to the Nasdaq Capital Market, according to a press release.

Under the engagement, Lucosky Brookman will prepare and file a registration statement on Form S-1 with the U.S. Securities and Exchange Commission, conduct due diligence related to the registration statement, and prepare responses to SEC comments and amendments. The firm will also handle the company's application for listing on a nationally recognized securities exchange.

If the uplisting proceeds, Lucosky Brookman

Form 8-K Adia Nutrition, Inc. For: Aug 19

Mon, 24 Aug 2026 08:00:00 -0400

si-local-file:///var/storage/secattach/20260824/26964441.html

Form 8-K Adia Nutrition, Inc. For: Aug 19

Mon, 24 Aug 2026 08:00:00 -0400

si-local-file:///var/storage/secattach/20260824/26964441.html

Adia Med Inc. Engages Lucosky Brookman LLP as Legal Counsel for Planned NASDAQ Uplisting

Mon, 24 Aug 2026 08:00:00 -0400

Winter Park, Florida--(Newsfile Corp. - August 24, 2026) - Adia Med Inc. (OTCQB: ADIA) today announced that it has entered into an engagement letter with Lucosky Brookman LLP ("Lucosky Brookman") to act as legal counsel in connection with the Company's planned uplisting from the OTC Markets to the NASDAQ Capital Market.

Lucosky Brookman LLP

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10520/310842_screenshot_lb_15_years.jpg

Under the engagement letter, Lucosky Brookman will provide services that include the preparation and/or review and filing of a registration

Adia Med Inc. Engages Lucosky Brookman LLP as Legal Counsel for Planned NASDAQ Uplisting

Mon, 24 Aug 2026 08:00:00 -0400

Lucosky Brookman LLP

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10520/310842_screenshot_lb_15_years.jpg

Under the engagement letter, Lucosky Brookman will provide services that include the preparation and/or review and filing of a registration

Form 8-K Adia Nutrition, Inc. For: Jul 10

Mon, 17 Aug 2026 14:56:00 -0400

si-local-file:///var/storage/secattach/20260817/26937581.html

Form 8-K Adia Nutrition, Inc. For: Jul 10

Mon, 17 Aug 2026 14:56:00 -0400

si-local-file:///var/storage/secattach/20260817/26937581.html

Adia Med Delivers Record Q2 Results: $485K Revenue, First Net Profit, and Nearly Matches Full-Year 2025 Revenue in First Half

Thu, 13 Aug 2026 12:07:00 -0400

Winter Park, Florida--(Newsfile Corp. - August 13, 2026) - Adia Med Inc. (OTCQB: ADIA), a regenerative medicine company focused on stem cell therapies, biologics, and advanced clinical services, today announced financial results for the second quarter ended June 30, 2026, as reported in its Form 10-Q filed with the Securities and Exchange Commission.

Inline Viewer: ADIA NUTRITION, INC. 10-Q 2026-06-30

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10520/309500_adiaimage.jpg

Second Quarter 2026 Highlights

Inline Viewer: ADIA NUTRITION, INC. 10-Q 2026-06-30

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10520/309500_adiaimage.jpg

Second Quarter 2026 Highlights

Full Sail University

To view an enhanced version of this graphic, please visit: